dc.contributor.author | de Man, Robert A. | |
dc.contributor.author | Senturk, Hakan | |
dc.contributor.author | Haagmans, Bart L. | |
dc.contributor.author | Schalm, Solko W. | |
dc.contributor.author | Janssen, Harry L. A. | |
dc.contributor.author | ter Borg, Martijn J. | |
dc.contributor.author | van Zonneveld, Monika | |
dc.contributor.author | Zeuzem, Stefan | |
dc.contributor.author | Akarca, Ulus S. | |
dc.contributor.author | Simon, Christopher | |
dc.contributor.author | Hansen, Bettina E. | |
dc.date.accessioned | 2021-03-04T14:07:36Z | |
dc.date.available | 2021-03-04T14:07:36Z | |
dc.date.issued | 2006 | |
dc.identifier.citation | ter Borg M. J. , van Zonneveld M., Zeuzem S., Senturk H., Akarca U. S. , Simon C., Hansen B. E. , Haagmans B. L. , de Man R. A. , Schalm S. W. , et al., "Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response", HEPATOLOGY, cilt.44, sa.3, ss.721-727, 2006 | |
dc.identifier.issn | 0270-9139 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_7fea0cf2-c27b-45a7-a61d-8bcc091d5183 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/87279 | |
dc.identifier.uri | https://doi.org/10.1002/hep.21302 | |
dc.description.abstract | In chronic hepatitis B, it is difficult to predict an early therapeutic response. We investigated the viral decline during therapy with pegylated interferon alpha-2b (PEG-IFN) with or without lamivudine in 266 HBeAg-positive chronic hepatitis B patients. In patients treated with PEG-IFN and lamivudine, a uniform biphasic viral decline pattern was found during therapy and there were no marked differences in viral load between those who lost HBeAg at the end of follow-up (response) or not. In contrast, those treated with PEG-IFN monotherapy exhibited different viral decline patterns. A delayed decline of at least two log from baseline HBV DNA after week 4 but before week 32 was associated with the highest response rate (63%). In comparison, response was 52% for patients with an early decline (week 0-4), 38% for a late decline (week 32-52), 27% for a posttreatment decline (week 52-78) and 11% for patients with no substantial decline. The HBsAg loss was 22% in the delayed decline pattern compared to 4% for those with early decline and none for other decline patterns. In conclusion, different patterns of decline in viral load during treatment with PEG-IFN monotherapy were associated with different rates of HBeAg and HBsAg loss at the end of follow-up. Since there was a considerable response, even in patients with a late or posttreatment decline pattern, prediction of response based on viral decline during the first months of therapy was difficult. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Gastroenteroloji-(Hepatoloji) | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
dc.title | Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response | |
dc.type | Makale | |
dc.relation.journal | HEPATOLOGY | |
dc.contributor.department | , , | |
dc.identifier.volume | 44 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 721 | |
dc.identifier.endpage | 727 | |
dc.contributor.firstauthorID | 179969 | |